See more : Quadient S.A. (QDT.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Empower Clinics Inc. (EPWCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Empower Clinics Inc., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- ACTIA Group S.A. (ATI.PA) Income Statement Analysis – Financial Results
- ABICO NetCom Co.,Ltd. (8071.TWO) Income Statement Analysis – Financial Results
- Great Eagle Holdings Limited (0041.HK) Income Statement Analysis – Financial Results
- Alterola Biotech, Inc. (ABTI) Income Statement Analysis – Financial Results
- Kratos Defense & Security Solutions, Inc. (0JS0.L) Income Statement Analysis – Financial Results
Empower Clinics Inc. (EPWCF)
About Empower Clinics Inc.
Empower Clinics Inc., an integrated healthcare company, provides body and mind wellness services for patients through digital and telemedicine care, and medical diagnostics laboratories in the United States and Canada. The company operates a pipeline of 33 clinics in Alberta, British Columbia, and New Brunswick. It has a strategic alliance with SoLVBL Solutions Inc. to develop a program for data security in diagnostic testing. Empower Clinics Inc. is based in Vancouver, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.66M | 4.37M | 3.21M | 2.03M | 1.09M | 1.56M | 2.13K | 0.00 | 17.00K | 17.00K | 1.89M | 1.32M | 912.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.69M | 3.02M | 1.19M | 826.28K | 417.05K | 768.90K | 718.11 | 0.00 | 0.00 | 8.64M | 12.25M | 4.76M | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.97M | 1.35M | 2.02M | 1.21M | 674.34K | 792.35K | 1.42K | 0.00 | 17.00K | -8.62M | -10.36M | -3.44M | -434.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 42.22% | 30.87% | 62.81% | 59.33% | 61.79% | 50.75% | 66.36% | 0.00% | 100.00% | -50,729.41% | -548.54% | -259.71% | -47.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 962.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.20M | 4.60M | 3.74M | 3.80M | 4.50M | 113.00K | 268.00K | 349.00K | 93.00K | 2.29M | 2.31M | 4.89M | 1.97M | 1.37M | 247.64K | 90.64K | 68.05K | 17.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 652.13K | 751.51K | 1.03M | 313.87K | 306.80K | 171.81 | 60.35 | 0.00 | 0.00 | 0.00 | 0.00 | 401.00K | 0.00 | 4.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.75M | 5.35M | 4.77M | 4.12M | 4.81M | 113.00K | 268.00K | 349.00K | 93.00K | 2.29M | 2.31M | 5.29M | 1.97M | 1.38M | 247.64K | 90.64K | 68.05K | 17.45K | 34.47K | 73.49K | 140.33K | 178.59K | 264.37K | 43.79K |
| Other Expenses | 173.07K | 1.41M | 850.85K | 604.31K | 829.43K | 0.00 | 0.00 | 23.02K | 469.00K | 765.00K | 3.52M | 4.84M | 1.22K | 5.88K | 37.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 730.76K | 856.23K | 64.85K |
| Operating Expenses | 6.92M | 6.75M | 5.62M | 4.72M | 4.98M | 113.00K | 268.00K | 349.00K | 562.00K | 3.06M | 5.83M | 5.29M | 2.94M | 1.38M | 285.18K | 90.64K | 68.05K | 17.45K | 34.47K | 73.49K | 140.33K | 909.34K | 1.12M | 108.63K |
| Cost & Expenses | 9.62M | 9.78M | 6.81M | 5.55M | 5.40M | 113.00K | 268.00K | 349.00K | 562.00K | 3.06M | 5.83M | 10.05M | 2.94M | 1.38M | 285.18K | 90.64K | 68.05K | 17.45K | 34.47K | 73.49K | 140.33K | 909.34K | 1.12M | 108.63K |
| Interest Income | 911.23K | 185.41K | 7.57K | 4.98K | 0.00 | 6.00K | 0.00 | 0.00 | 0.00 | 3.03M | 2.48M | 43.00K | 398.00 | 0.00 | 40.06K | 0.00 | 31.87K | 360.00 | 0.00 | 1.29K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.55M | 185.41K | 539.41K | 355.05K | 367.90K | 0.00 | 0.00 | 0.00 | 0.00 | 30.00K | 745.00K | 109.00K | 0.00 | 0.00 | -285.18K | -90.64K | -35.40K | -18.75K | -64.09K | -341.81K | -137.40K | -893.77K | -1.11M | -108.63K |
| Depreciation & Amortization | 205.04K | 535.12K | 188.38K | 334.66K | 117.18K | 107.09K | 106.17K | 55.00K | 45.00K | 88.00K | 96.00K | 80.00K | 1.22K | 14.71K | 2.52K | 65.31K | 1.23K | 415.00 | 565.00 | 772.00 | 1.06K | 1.44K | 410.00 | 11.47K |
| EBITDA | -1.09M | -30.74M | -16.84M | -3.70M | -3.13M | -2.23M | -212.41K | -247.76K | 743.78K | -5.39M | -4.35M | -9.66M | -2.02M | -1.50M | -268.33K | 0.00 | -36.17K | -19.35K | -66.53K | -72.72K | -138.34K | -907.91K | -1.12M | -108.63K |
| EBITDA Ratio | -23.35% | -105.37% | -100.14% | -140.57% | -307.54% | -9.67% | -15,036.14% | 0.00% | -10,670.59% | 447.06% | -72.42% | -650.26% | -222.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.95M | -5.41M | -3.61M | -3.52M | -4.31M | -113.00K | -268.00K | -349.00K | 772.00K | -8.64M | -12.25M | -9.95M | -2.03M | -1.38M | -285.18K | -90.64K | -68.05K | -17.45K | -34.47K | -73.49K | -140.33K | -893.77K | -1.11M | -108.63K |
| Operating Income Ratio | -106.28% | -123.75% | -112.35% | -173.02% | -394.85% | -7.24% | -12,553.53% | 0.00% | 4,541.18% | -50,829.41% | -648.54% | -752.23% | -222.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.11M | -26.29M | -13.09M | -163.45K | 519.46K | -3.11M | -1.00K | 49.74K | 1.27M | -2.27M | -6.06M | -66.00K | 398.00 | 14.71K | 2.52K | 65.31K | 31.87K | -1.33K | -29.62K | -268.32K | 2.93K | 0.00 | 0.00 | 11.47K |
| Income Before Tax | -2.84M | -31.74M | -17.07M | -4.30M | -3.79M | -75.00K | -215.00K | -269.00K | 735.00K | -5.64M | -10.52M | -10.02M | -2.03M | -1.37M | -282.66K | -25.33K | -36.17K | -18.77K | -64.09K | -341.81K | -137.40K | -893.77K | -1.11M | -97.17K |
| Income Before Tax Ratio | -61.00% | -726.41% | -531.79% | -211.74% | -347.26% | -4.80% | -10,070.93% | 0.00% | 4,323.53% | -33,200.00% | -556.70% | -757.22% | -222.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 165.00 | 968.67K | 542.21K | 812.18K | -519.46K | -38.00K | -53.00K | -55.00K | 37.00K | 2.61M | 41.00K | 33.00K | 6.22K | 1.37M | 282.66K | 25.33K | 36.17K | 18.77K | 64.09K | 341.81K | 137.40K | 893.77K | 1.11M | 97.17K |
| Net Income | -2.83K | -32.70M | -17.61M | -5.11M | -3.79M | -75.00K | -215.00K | -269.00K | 735.00K | -5.64M | -8.55M | -10.05M | -2.03M | -1.37M | -282.66K | -25.33K | -36.17K | -18.77K | -64.09K | -341.81K | -137.40K | -893.77K | -1.11M | -97.17K |
| Net Income Ratio | -0.06% | -748.58% | -548.69% | -251.72% | -347.26% | -4.80% | -10,070.93% | 0.00% | 4,323.53% | -33,200.00% | -452.83% | -759.71% | -222.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.50 | -0.48 | -0.22 | -0.28 | -0.02 | -0.06 | -0.09 | 0.30 | -2.34 | -4.83 | -7.55 | -2.43 | -3.89 | -0.91 | -0.08 | -0.13 | -0.08 | -0.29 | -1.44 | -0.53 | -3.75 | -5.25 | -0.75 |
| EPS Diluted | -0.04 | -0.50 | -0.48 | -0.22 | -0.28 | -0.02 | -0.06 | -0.09 | 0.30 | -2.34 | -4.83 | -7.55 | -2.43 | -3.89 | -0.91 | -0.08 | -0.13 | -0.08 | -0.29 | -1.44 | -0.53 | -3.75 | -5.25 | -0.75 |
| Weighted Avg Shares Out | 70.21M | 65.60M | 36.47M | 23.46M | 13.33M | 3.42M | 3.42M | 3.09M | 2.43M | 2.41M | 1.77M | 1.33M | 835.20K | 352.20K | 309.33K | 309.33K | 268.96K | 221.33K | 221.33K | 237.88K | 261.33K | 238.34K | 210.76K | 129.55K |
| Weighted Avg Shares Out (Dil) | 70.21M | 65.60M | 36.47M | 23.46M | 13.33M | 3.42M | 3.42M | 3.09M | 2.43M | 2.41M | 1.77M | 1.33M | 835.20K | 352.20K | 309.33K | 309.33K | 268.96K | 221.33K | 221.33K | 237.88K | 261.33K | 238.34K | 210.76K | 129.55K |
Empower Clinics Provides Corporate Update
VANCOUVER, BC / ACCESSWIRE / August 18, 2023 / EMPOWER CLINICS INC (CSE:EPW)(OTC PINK:EPWCF) ("Empower" or the "Company") an integrated healthcare company with a developing research and clinical trials division announces various corporate updates. CEASE TRADE ORDER On August 15th,...
Empower Clinics Announces Closing of Second Tranche Private Placement Financing
VANCOUVER, BC / ACCESSWIRE / August 15, 2023 / Empower Clinics Inc. ("Empower" or the "Company") (CSE:EPW)(OTC PINK:EPWCF), is pleased to announce that it has closed a second tranche private placement of units of the Company (the "Units"), pursuant to...
Empower Clinics Announces Closing of First Tranche Private Placement Financing
VANCOUVER, BC / ACCESSWIRE / August 9, 2023 / Empower Clinics Inc. ("Empower" or the "Company") (CSE:EPW)(OTC PINK:EPWCF), is pleased to announce that it has closed a first tranche private placement of units of the Company (the "Units"), pursuant to...
Empower Clinics Announces Proposal For Division Spin Out
VANCOUVER BC / ACCESSWIRE / August 1, 2023 / EMPOWER CLINICS INC. (CSE:EPW)(OTC PINK:EPWCF) ("Empower" or the "Company") announces today, after a strategic review, the Company has determined that it intends to complete a direct spin out of a wholly...
Empower Clinics Signs New Agreements To Advance Growth Of Research and Clinical Trials with Signing Of Two Additional Principal Investigators - And Are Approved To Process Multiple Clinical Study Applications From Pharmaceutical Sponsors
Multiple Research Studies Are In Official Application Stage For EPW Curesearch Sites Covering Numerous Protocols And Specialties VANCOUVER, BC / ACCESSWIRE / July 31, 2023 / EMPOWER CLINICS INC (CSE:EPW)(OTCQB:EPWCF) ("Empower" or the "Company") a healthcare company with a developing...
Empower Clinics signs letter of intent for equity capital facility
Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) said it has signed a letter of intent (LOI) with Crescita Capital LLC for a C$5 million equity capital facility. The capital facility is intended to be used for general working capital purposes, strategic business development and...
Empower Clinics looks to expand research opportunities, utilize financial advisor to grow shareholder value
Empower Clnincs Inc. has released a corporate update covering its developing research and clinical trials divisions. Last month, Empower subsidiary EPW Curesearch LLC announced an agreement to develop a program for research and clinical trials services with a Dallas, Texas-based...
Empower Clinics signs fourth principal investigator for Dallas site
Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) announced that it has signed another agreement for a principal investigator (PI) at its research and clinical trial site in Dallas, Texas. This brings the number of experienced researchers at the site to four, paving...
Empower Clinics adds two new researchers to support clinical trials services at its site in Dallas
Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) said its subsidiary, EPW Curesearch LLC, has signed two new research services agreements with leading physicians and researchers to support clinical trials services at its first research site in Dallas, Texas. The additions bring the active count...
Empower Clinics signs clinical trials services deal with Texas medical group
Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) has announced an agreement to develop a program for research and clinical trials services with a Dallas, Texas-based medical center. Under the deal, Empower subsidiary EPW Curesearch LLC (EPWC) will provide pharmaceutical research and clinical trial services,...
Source: https://incomestatements.info
Category: Stock Reports